Breaking: The PharmaJet® Tropis® Needle-Free Injection System Has Been Picked To Administer 1.4 Million Doses Of Polio Vaccine In Nigeria
The PharmaJet Tropis needle-free intradermal (ID) injection system will be used to administer approximately 1.4 million doses of polio vaccine as part of a campaign in Nigeria
By Clifford Agugoesi, Editor-in-Chief
A global leader in needle-free injection technology, PharmaJet today announced that its WHO-prequalified Tropis needle-free ID injection system will be used to administer approximately 1.4 million doses of fractionated inactivated polio vaccine (fIPV) during upcoming polio immunization campaigns in Nigeria, Cyber Era NG learns.
We gather that PharmaJet is partnering with the African Field Epidemiology Network (AFENET) to deploy Tropis to administer fIPV to children under 5 years of age in Sokoto, a state in northwestern Nigeria.
Nigeria remains free of wild poliovirus but continues to experience outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2). According to national surveillance data, 66 cases were reported in 2025.
The country remains committed to ending all poliovirus transmission by 2030 by investing in surveillance, routine immunization, and supplementary immunization campaigns (SICs). Polio vaccination has been integrated into broader health initiatives through campaigns and community outreach activities aimed at vaccinating all eligible children.<sup>5</sup> In this context, needle-free intradermal administration of fractionated doses of IPV expands vaccination coverage while reducing costs and logistical complexity.<sup>1,4</sup>
The large-scale use of needle-free Tropis administration in Sokoto follows a large randomized controlled trial of fractionated IPV administration via Tropis in routine immunization, conducted in collaboration with PATH, Jhpiego, the National Primary Health Care Development Agency (NPHCDA), and Sydani.
The study, conducted in Nigeria and published in Vaccines4, demonstrated that, compared to the standard of care (full dose administered using needles), Tropis administration resulted in:
an 11.2% higher coverage for the second dose of IPV (IPV2)
a reduction of up to 47% in the total cost of vaccination
a preference of 97% among healthcare professionals
a reduction in administration time
all forms of Polio by 2030,6 nov. 2025. –With additional reporting by Godson Umejiego, Bureau Chief, The Americas and Kingsley I. Ilechukwu, Bureau Chief, South West, Nigeria.
